This company has been marked as potentially delisted and may not be actively trading. 2seventy bio (TSVT) Stock Forecast & Price Target Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsEarningsFDA EventsHeadlinesInsider TradesOwnershipShort InterestTrendsBuy This Stock Get the Latest News and Ratings for TSVT and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 2seventy bio and its competitors. Enter your email to sign up for newsletter Sign Up TSVT Analyst Ratings Over TimeTypeCurrent Forecast8/2/24 to 8/2/251 Month Ago7/3/24 to 7/3/253 Months Ago5/4/24 to 5/4/251 Year Ago8/3/23 to 8/2/24Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)1 Strong Buy rating(s)Buy0 Buy rating(s)0 Buy rating(s)1 Buy rating(s)4 Buy rating(s)Hold3 Hold rating(s)3 Hold rating(s)4 Hold rating(s)4 Hold rating(s)Sell0 Sell rating(s)0 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$5.00$5.00$5.60$11.43Forecasted UpsideN/AN/A12.00% Upside178.75% UpsideConsensus RatingHoldHoldHoldModerate Buy TSVT Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History TSVT Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table 2seventy bio Stock vs. The CompetitionType2seventy bioMedical CompaniesS&P 500Consensus Rating Score 2.00 2.81 2.53Consensus RatingHoldModerate BuyModerate BuyPredicted UpsideN/A10,285.41% Upside14.62% UpsideNews Sentiment RatingNeutral NewsSee Recent TSVT NewsPositive NewsPositive News Recent Analyst Forecasts and Stock Ratings All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Years 5 Years Time Frame Start Date End Date Most Recent from Each Brokerage All Show Export to Excel DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails5/10/2025Weiss Ratings0 of 5 stars Reiterated RatingSell (E+) ➝ Sell (D-)3/14/2025Morgan Stanley3 of 5 starsMatthew HarrisonSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower TargetEqual Weight ➝ Equal Weight$6.00 ➝ $5.00+1.01%3/11/2025Leerink Partnrs1 of 5 starsD. GrayboschSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/11/2025Leerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDaina GrayboschSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$9.00 ➝ $5.00+78.57%6/27/2024WedbushSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingNeutral ➝ Neutral$5.00 ➝ $5.00+28.53%6/6/2024The Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeNeutral ➝ Sell$5.00 ➝ $2.00-56.14%5/9/2024Canaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingJ. NewmanSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/8/2024CitigroupSubscribe to MarketBeat All Access for the recommendation accuracy rating Boost TargetBuy ➝ Buy$9.00 ➝ $12.00+117.79%1/31/2024TD CowenSubscribe to MarketBeat All Access for the recommendation accuracy rating Reiterated RatingOutperform ➝ Market Perform9/12/2023GuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy rating DowngradeBuy ➝ Neutral Get the Latest News and Ratings for TSVT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for 2seventy bio and its competitors with MarketBeat's FREE daily newsletter. Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:55 AM ET. TSVT Forecast - Frequently Asked Questions What is 2seventy bio's forecast for 2025? According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for 2seventy bio is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. Should I buy or sell 2seventy bio stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 2seventy bio in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" TSVT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TSVT, but not buy additional shares or sell existing shares. What analysts cover 2seventy bio? 2seventy bio has been rated by research analysts at Weiss Ratings in the past 90 days. Do Wall Street analysts like 2seventy bio more than its competitors? Analysts like 2seventy bio less than other "medical" companies. The consensus rating for 2seventy bio is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how TSVT compares to other companies. Stock Forecasts and Research Tools Related Companies Amphastar Pharmaceuticals Stock Forecast Iovance Biotherapeutics Stock Forecast Enliven Therapeutics Stock Forecast Anavex Life Sciences Stock Forecast Structure Therapeutics Stock Forecast Ardelyx Stock Forecast Collegium Pharmaceutical Stock Forecast Verve Therapeutics Stock Forecast Oric Pharmaceuticals Stock Forecast ProKidney Stock Forecast Today's Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter This page (NASDAQ:TSVT) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 2seventy bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
